... On June 3, 2025, the Company issued a press release the (the “Press Release”) announcing the publication of clinical efficacy data for recessive dystrophic epidermolysis bullosa associated locally advanced or metastatic squamous cell carcinoma patients treated with rigosertib in an investigator sponsored, open-label, single arm Phase 2 study. The results of the study indicated an overall response rate of 80% with complete responses in 50% of evaluable patients. A copy of the Press Release is filed herewith as Exhibit 99.3 and is incorporated by reference into this Item 8.01....
Market Data 
Markets 
AI
